Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ANAC's 30-Y Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology  
Traded in other countries:44A.Germany,
Headquarter Location:USA
Anacor Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform.

Anacor Pharmaceuticals Inc was incorporated in Delaware in December 2000 and began business operations in March 2002. It is a biopharmaceutical company engaged in discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It has discovered, synthesized and developed eight molecules that are currently in development. The Company's main product candidates include two topically administered dermatologic compounds, tavaborole (formerly referred to as AN2690) and AN2728. Tavaborole is a topical treatment for onychomycosis, a fungal infection of the nail and nail bed. AN2728 is its main topical anti-inflammatory product candidate for the treatment of atopic dermatitis and psoriasis, chronic inflammatory skin diseases that affect millions of people. In addition, the Company has three other wholly-owned clinical product candidates; AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365 (formerly referred to as GSK2251052, or GSK '052), an antibiotic for the treatment of infections caused by Gram-negative bacteria, which previously was licensed to GlaxoSmithKline LLC (GSK). It has also discovered three other compounds that it has out-licensed for further development; one is licensed to Eli Lilly and Company (Lilly), for the treatment of an animal health indication; a second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative (DNDi), for human African trypanosomiasis (HAT, or sleeping sickness); and a third compound is licensed to GSK for tuberculosis (TB). As of February 1, 2014, the company was the owner of record, either solely or with a collaborator, of 23 issued U.S. patents. The Company and its third-party manufacturers are subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of its products to assess its compliance with applicable regulations.

Guru Investment Theses on Anacor Pharmaceuticals Inc

Royce Funds Comments on Anacor Pharmaceuticals - Oct 12, 2015

Anacor Pharmaceuticals (ANAC) continues to benefit from the recent launch of its first commercial product, Kerydin, a topical antifungal medication, and positive top-line results from two pivotal Phase 3 studies of Crisaborole, a topical treatment for atopic dermatitis.

From "Staying Diversified in the Pursuit of Sustainable Growth - Royce Funds Commentary."

Check out Chuck Royce latest stock trades



Buy Back


Valuation & Return


More Statistics

Revenue (TTM) (Mil) $84.63
EPS (TTM) $ -1.46
Short Percentage of Float16.96%
52-Week Range $52.00 - 156.93
Shares Outstanding (Mil)45.37

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 77 390 859
EPS ($) -1.34 3.39 7.45
EPS without NRI ($) -1.34 3.39 7.45
EPS Growth Rate
(Future 3Y To 5Y Estimate)
Dividends per Share ($)
» More Articles for ANAC


Articles On GuruFocus.com
Charlie Tian's Interview on The Next Level Show Jun 28 2017 
Paulson Dives Deeper Into Valeant With Increased Holding Jun 27 2017 
US Market Indexes Lower, Technology Stock Volatility a Factor Jun 27 2017 
General Mills to Release 4th-Quarter, Full-Fiscal 2017 Results Jun 27 2017 
Warren Buffett Interprets the State of the Economy on PBS Newshour Jun 27 2017 
Office Space Provider Is a Good Stock to Follow Jun 27 2017 
Don't Lose Your Faith in Cisco Systems Jun 27 2017 
The Future of Value Investing Jun 27 2017 
Quotes From 2 of the World's Greatest Value Investors Jun 27 2017 
Extracts From the Bible of Value Investing Jun 27 2017 

More From Other Websites
New Product Launches May Boost Valeant’s Dermatology Revenue Mar 23 2017
AnacorAcquisition Added Crisaborole to Pfizer’s Portfolio Nov 17 2016
What Investors Should Know about the Pfizer-Anacor Deal Aug 29 2016
Why Pfizer's Acquisition of Anacor Is a Great Fit Aug 18 2016
Pfizer-Anacor Deal Completed in June 2016 Aug 12 2016
Will Pfizer Book Another Healthy Quarter? Jul 22 2016
What Can We Expect from the Pfizer-Anacor Deal? Jul 06 2016
The Pfizer-Anacor Deal Wrapped Up in June: Now What? Jul 06 2016
Pfizer Completes Anacor Acquisition Jun 24 2016
Why Pfizer (PFE) is a Great Stock to Buy for the Long Run Jun 23 2016
Will A New Suitor For Anacor Emerge? Jun 15 2016
Why Anacor Pharmaceuticals, Inc. Stock Jumped 58.3% in May Jun 05 2016
Better Buy: Novavax, Inc. vs. Pfizer Inc. May 30 2016
How Wellcome and Gates charities profit from helping biotech May 30 2016
Anacor received rival bid before Pfizer deal - filing May 26 2016
Buy Pfizer, Chevron, Newell Brands and Enjoy the Profits May 25 2016
Why Pfizer, Chevron and Newell Brands Could be Great For Your Portfolio May 25 2016
XBI’s and IHI’s Mid-Caps Soared, Overturning 2 Weeks of Losses May 25 2016
Pfizer's Buyout of Anacor Pharmaceuticals for $5.2 Billion Is a Bad Move -- Here's Why May 24 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat